Louise Carter

Clinical Senior Lecturer

The University of Manchester

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Louise Carter is a Clinical Senior Lecturer at the University of Manchester, United Kingdom. Her research focuses on improving outcomes for cancer patients through innovative tools and methodologies, including the development of the SCNS-TARGET tool and evaluations of early phase clinical trials for rare cancers. She also investigates the social determinants of health inequalities and enhances personalized medicine through comprehensive studies on molecular tumour boards and patient reported experiences.

Articles (11)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (10)

Patricia Roxburgh

University of Glasgow

UNITED KINGDOM

View details

Gerald Falchook

UNITED STATES

View details

Rebecca S. Kristeleit

University of Arizona College of Medicine

UNITED STATES

View details

Debashis Sarker

King’s College London

UNITED KINGDOM

View details

ROBERT JONES

Professor

Cardiff University

UNITED KINGDOM

View details

Ruth Plummer

Clinical Professor

Newcastle University

UNITED KINGDOM

View details

Elena Garralda

SPAIN

View details

chelsea sawyer

The University of Manchester

UNITED KINGDOM

View details

Natalie Cook

The University of Manchester

UNITED KINGDOM

View details

BABAR BASHIR

Assistant Professor

Thomas Jefferson University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Louise Carter

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

A single centre experience of patients with Rare Cancers referred for Early Phase Clinical Trials

Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients

Development of the SCNS-TARGET: a new tool to assess unmet needs in cancer patients utilising immuno-, biological or precision therapies

Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)

Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors

Social determinants of health inequalities in early phase clinical trials in Northern England

647P EphA2-targeting bicycle toxin conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: A phase I/II study

Sex as a Biological Variable in Early-Phase Oncology Clinical Trials: Enhancing the Path to Personalised Medicine

Development and validation of a Patient Reported Experience Measure for Experimental Cancer Medicines (PREM-ECM) and their carers (PREM-ECM-Carer)

PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

Collaborators (10)

Patricia Roxburgh

Gerald Falchook

Rebecca S. Kristeleit

Debashis Sarker

ROBERT JONES

Ruth Plummer

Elena Garralda

chelsea sawyer

Natalie Cook

BABAR BASHIR

Make your next move.